Labs / CDMO: development & manufacturing
Sarcomatrix
Reno, NV, United States · sarcomatrix.com
GMP
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Sarcomatrix is a clinical-stage rare disease pharmaceutical company developing therapies for muscle-wasting diseases, including Duchenne muscular dystrophy, sarcopenia, and cachexia. It is based in Reno, Nevada, and works on preclinical and early clinical development of muscle regeneration therapies.
Their website has a general contact form; we send your quote request through it.
What they offer
Drug discovery platform for muscle-wasting diseases
Uses SarcoScreen™ to identify and advance novel therapies for muscle-wasting diseases through functional assays on muscle cells.
Functional screening of compounds
Assesses compounds for effects such as enhanced regeneration, protection from injury, and restored contractile function in muscle cells.
Translational research
Supports movement of programs from research into preclinical and IND-enabling studies.
IND-enabling studies
Conducts studies to prepare programs for Investigational New Drug submission.
Clinical trial design and execution
Brings experience in designing and executing clinical trials for muscle disease programs.
CMC support
Provides chemistry, manufacturing, and controls work for therapeutic development.
GMP manufacturing
States that it is initiating GMP manufacturing of main components.
Supply chain management
Works on supply chain planning and partner selection for commercial-grade production.
Regulatory strategy
Manages regulatory communications and has experience securing orphan drug and rare pediatric disease designations.
Market access and commercialization support
Builds brand recognition and navigates market access pathways for therapies.
What they work on
- Modalities
- Small molecule
- Assays and studies
- functional assays
- Therapeutic areas
- Duchenne muscular dystrophy, muscular dystrophy, sarcopenia, cachexia, LAMA2-RD, muscle-wasting diseases
- Minimums and prices
- Targeting a $5 million raise · An initial $750,000 sought by third quarter of 2025
- Sites
- Reno, USA
- Quality
- GMP (Good Manufacturing Practice) (main components) · Quality by design
- Address
- 450 Sinclair Street, Reno, NV 89501 USA
Similar labs. Antheia, CDI Labs, Nuvisan, Sai Life
Found in a contract services directory. Listing built from sarcomatrix.com. Work here? Claim this listing.